Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

Andrew Kuykendall, Francesca Palandri, Bella Vo, Fulya Sen Nikitas, Nicholas Meader, Shiyuan Zhang, Tom (sizhu) Liu, Shuang Wang, Gautam Sajeev, Mirko Fillbrunn, James Signorovitch, Jasmine Sahni, Dwaipayan Patnaik, Aaron Gerds

Blood (2025) 146 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2025-2031

Published: 2025

Journal Articles

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

Francesca Palandri, Nicolaas Schaap, Jérôme Rey, Nikolas Von Bubnoff, Andreas Reiter, Juan Carlos Hernandez Boluda, Timothy Devos, Bethan Psaila, Donal McLornan, Catherine Ellis, Fulya Sen Nikitas, Shiyuan Zhang, Jessica Lim, Dwaipayan Patnaik, Stephen Oh

Blood (2025) 146 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2025-2023

Published: 2025

Journal Articles

Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia

Yi Zhu, Xiwen Tong, Bin Xu, Shiyuan Zhang, Andie Fu, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 6989.

https://doi.org/10.1182/blood-2025-6989

Published: 2025

Journal Articles

ZFP36L2 as a promising therapeutic target in acute graft-versus-host disease: Evidence from murine models and clinical validation

Li Li, Andie Fu, Xiwen Tong, Bin Xu, Xia Mao, Ying Wang, Shiyuan Zhang, Yi Zhu, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 5863.

https://doi.org/10.1182/blood-2025-5863

Published: 2025

Journal Articles

SH2B3 expression predicts selinexor sensitivity in acute myeloid leukemia

Shiyuan Zhang, Longlong Liu, Bin Xu, Xiwen Tong, Andie Fu, Shuai Su, Yi Zhu, Zhuoxin Wen, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 7016.

https://doi.org/10.1182/blood-2025-7016

Published: 2025

Journal Articles

Rapid bone marrow blast reduction-guided selinexor-based regimen therapy in relapsed/refractory and newly diagnosed acute myeloid leukemia

Yi Zhu, Shuai Su, Bin Xu, Shiyuan Zhang, Zhuoxin Wen, Xiwen Tong, Andie Fu, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 5223.

https://doi.org/10.1182/blood-2025-5223

Published: 2025

Journal Articles

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials

Francesca Palandri, Casey O'Connell, Pankit Vachhani, Donal McLornan, Steffen Koschmieder, Juan Carlos Hernandez Boluda, Catherine Ellis, Tom (sizhu) Liu, Shiyuan Zhang, Jessica Lim, Dwaipayan Patnaik, Vikas Gupta

Blood (2025) 146 (Supplement 1): 5581.

https://doi.org/10.1182/blood-2025-5581

Published: 2025

Journal Articles

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

Raajit Rampal, Prithviraj Bose, Vikas Gupta, Francesca Palandri, Shiyuan Zhang, Jessica Lim, Fulya Sen Nikitas, Tom (sizhu) Liu, Jasmine Sahni, Catherine Ellis, Dwaipayan Patnaik, Florian Heidel, Francesco Passamonti

Blood (2025) 146 (Supplement 1): 5579.

https://doi.org/10.1182/blood-2025-5579

Published: 2025

Journal Articles

Selinexor-based non-intensive chemotherapy regimens adjusted according to early responses achieve high early remission in newly diagnosed AML or MDS

Shiyuan Zhang, Shuai Su, Bin Xu, Xiwen Tong, Yi Zhu, Andie Fu, Zhuoxin Wen, Zhiqiong Wang, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 1673.

https://doi.org/10.1182/blood-2025-1673

Published: 2025

Journal Articles

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Vikas Gupta, Francesca Palandri, Jean-Jacques Kiladjian, Bethan Psaila, Bella Vo, Jessica Lim, Fulya Sen Nikitas, Shiyuan Zhang, Tom (sizhu) Liu, Catherine Ellis, Jasmine Sahni, Dwaipayan Patnaik, Stephen Oh, Ruben Mesa

Blood (2025) 146 (Supplement 1): 3809.

https://doi.org/10.1182/blood-2025-3809

Published: 2025

Journal Articles

Impact of Selinexor on AML Cell Lines and Healthy Donor T Cell Function: Enhanced Treg Cell Proportion

Xiwen Tong, Xiaojian Zhu, Su Shuai, Yi Zhu, Bin Xu, Yizhou Peng, Shiyuan Zhang, Jin Jie, Xia Mao, Jia Wei, Donghua Zhang

Blood (2024) 144 (Supplement 1): 5817.

https://doi.org/10.1182/blood-2024-205174

Published: 2024

Journal Articles

Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States

Andrew T. Kuykendall, Francesca Palandri, Shiyuan Zhang, Tom Liu, Mirko Fillbrunn, Adina Zhang, Gautam Sajeev, James Signorovitch, Dwaipayan Patnaik, Aaron T. Gerds

Blood (2024) 144 (Supplement 1): 3804.

https://doi.org/10.1182/blood-2024-205380

Published: 2024

Journal Articles

The Relationship between Anemia, Transfusion Dependence, Quality of Life and Survival in Myelofibrosis

Aaron T. Gerds, Fulya Sen Nikitas, Shiyuan Zhang, Molly Purser, Seán Conlon, Anuja Pandey, Ike Iheanacho, Balazs Dobi, Venediktos Kapetanakis

Blood (2024) 144 (Supplement 1): 6677.

https://doi.org/10.1182/blood-2024-207828

Published: 2024

Journal Articles

Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison

Francesca Palandri, Venediktos Kapetanakis, Balazs Dobi, Filippo Branzanti, Catherine Ellis, Nick Ballew, Tom Liu, Kelesitse Phiri, Fulya Sen Nikitas, Melania Biasi, Shiyuan Zhang, Dwaipayan Patnaik

Blood (2024) 144 (Supplement 1): 3187.

https://doi.org/10.1182/blood-2024-205973

Published: 2024

Journal Articles

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

Shiyuan Zhang, Mengyuan Li, Xiaojian Zhu, Hao Zhou, Bin Xu, Xiwen Tong, Su Shuai, Yi Zhu, Yi Xiao, Liang Huang, Dengju Li, Wei Huang, Jia Wei, Mei Huang, Donghua Zhang

Blood (2024) 144 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2024-205864

Published: 2024

Journal Articles

Prognostic and Therapeutic Implications of Early Assessment in AML and MDS Patients Treated with Selinexor-Containing Chemotherapy-Free Regimen

Su Shuai, Bin Xu, Xiwen Tong, Yi Zhu, Shiyuan Zhang, Xia Mao, Zhiqiong Wang, Min Xiao, Donghua Zhang, Jia Wei

Blood (2024) 144 (Supplement 1): 6004.

https://doi.org/10.1182/blood-2024-205664

Published: 2024

Journal Articles

Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis

Thomas W. LeBlanc, Hannah Collacott, Valentín García Gutiérrez, Sr., Ned Weinshenker, Ruth Fein Revell, Alicia O'Neill, Anna P Cardellino, Shiyuan Zhang, Dwaipayan Patnaik, Melissa Ross

Blood (2024) 144 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2024-206086

Published: 2024

Journal Articles

Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Xiwen Tong, Bin Xu, Shiyuan Zhang, Xiaojian Zhu, Mengyuan Li, Su Shuai, Yi Zhu, Zhenqian Huang, Yaya Wang, Yi Xiao, Liang Huang, Dengju Li, Wei Huang, Jia Wei, Mei Huang, Zhiping Huang, Yuanyan Tang, Hongbo Ren, Donghua Zhang

Blood (2024) 144 (Supplement 1): 4276.

https://doi.org/10.1182/blood-2024-205769

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia

ZFP36L2 as a promising therapeutic target in acute graft-versus-host disease: Evidence from murine models and clinical validation

SH2B3 expression predicts selinexor sensitivity in acute myeloid leukemia

Rapid bone marrow blast reduction-guided selinexor-based regimen therapy in relapsed/refractory and newly diagnosed acute myeloid leukemia

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

Selinexor-based non-intensive chemotherapy regimens adjusted according to early responses achieve high early remission in newly diagnosed AML or MDS

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Impact of Selinexor on AML Cell Lines and Healthy Donor T Cell Function: Enhanced Treg Cell Proportion

Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States

The Relationship between Anemia, Transfusion Dependence, Quality of Life and Survival in Myelofibrosis

Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

Prognostic and Therapeutic Implications of Early Assessment in AML and MDS Patients Treated with Selinexor-Containing Chemotherapy-Free Regimen

Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis

Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only